Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 10 of 10 for “"dyW"”.

  1. Efficacy of losartan and growth hormone combinatorial therapy in DyW mice

    … MDC1A patients. In this study we use the Lama2dyW (DyW) mouse model which shares analogous phenotypes with the MDC1A disease in humans. To this point, therapy development has mainly utilized single-mode therapy. While effective in attenuating some aspects of pathology, no single treatment has …

    bu Repository record for Efficacy of losartan and growth hormone combinatorial therapy in DyW mice (opens in a new tab)

  2. Muscle Fiber Characterization of the DyW Animal Model of Laminin Alpha 2 Congenital Muscular Dystrophy

    Laminin-α2 congenital muscular dystrophy (LAMA2-CMD) is a rare disease affecting children as early as birth. It is a result of mutations in the LAMA2 gene responsible for coding the laminin alpha 2 chain. The alpha chain is one-third of an essential protein and significant component of the basement …

    unr Repository record for Muscle Fiber Characterization of the DyW Animal Model of Laminin Alpha 2 Congenital Muscular Dystrophy (opens in a new tab)

  3. Production and purification of recombinant human laminin-111 for pre-clinical testing in a murine model of laminin-α2 deficient congenital muscular dystrophy

    … Burkin lab has shown effective treatment of the dyW mouse model of LAMA2-CMD through successful substitution of these adult laminin isoforms using injections of the mouse embryonic laminin isoform, laminin-111. What has not been explored in these studies is whether the dyW mouse model could also …

    unr Repository record for Production and purification of recombinant human laminin-111 for pre-clinical testing in a murine model of laminin-α2 deficient congenital muscular dystrophy (opens in a new tab)

  4. Studies On Trans-Acting Factors Involved In Chloroplast Rna Editing In Arabidopsis Thaliana

    … C-terminal motifs called the E domain and the DYW domain, where the DYW domain features amino acids conserved with the active site in other cytidine deaminases. I examined the DYW motifs of two chloroplast PPR-DYW editing factors: REQUIRED FOR ACCD RNA EDITING 1 (RARE1), which is responsible …

    cornell Repository record for Studies On Trans-Acting Factors Involved In Chloroplast Rna Editing In Arabidopsis Thaliana (opens in a new tab)

  5. Enhanced alpha7beta1 integrin prevents muscle disease in a mouse model of congenital muscular dystrophy

    … expression in the skeletal muscle of the dyW-/- mouse model of MDC1A. The dyW-/- mouse is one of the most commonly used models of MDC1A and displays altered expression and localization of the α7 integrin with little integrin appropriately localized to the sarcolemma. We accomplished …

    unr Repository record for Enhanced alpha7beta1 integrin prevents muscle disease in a mouse model of congenital muscular dystrophy (opens in a new tab)

  6. The role of recombinant human laminin-111 in adhesion-signaling and glycosylation in laminin-⍺2 deficient muscle

    … glycolysis. In the LAMA2-CMD mouse model, the dyW, spatial proteomics showed similar altered proteins and dysregulated pathways to LAMA2-CMD patients. Including downregulation of MAPK and Akt signaling. After treatment with recombinant human laminin-111 (rhLAM-111), the differentially expressed …

    unr Repository record for The role of recombinant human laminin-111 in adhesion-signaling and glycosylation in laminin-⍺2 deficient muscle (opens in a new tab)

  7. A New Congenital Mouse Model to Study Laminin Protein Therapy for Muscular Dystrophy

    … muscle pathology and improve viability in the dyW-/- mouse model of MDC1A. These studies suggested that laminin-111 may act to strengthen and reinforce the sarcolemma and provide a protective niche for muscle repair. Since most patients are diagnosed with MDC1A after disease onset, we …

    unr Repository record for A New Congenital Mouse Model to Study Laminin Protein Therapy for Muscular Dystrophy (opens in a new tab)

  8. Laminin-111 Protein Therapy for the Treatment of Merosin Deficient Congenital Muscular Dystrophy Type 1A

    … the regenerative capacity of muscle, the dyW-/- animal model of MDC1A was pretreated intramuscularly with EHS derived mouse laminin-111 prior to injury with cardiotoxin and mice then received weekly booster treatments to observe the impact on muscle repair and regeneration. Our results …

    unr Repository record for Laminin-111 Protein Therapy for the Treatment of Merosin Deficient Congenital Muscular Dystrophy Type 1A (opens in a new tab)